<< Back to Results
A Phase Ib study of intermittent administration of high doses of the irreversible EGFR inhibitor afatinib as a means of achieving plasma levels active against non-small cell lung cancer with known T790M mutations
- Objective
- Not available at this time
- IRB Protocol Number
- 12-0610
- Principal Investigator(s)
- ROSS CAMIDGE
-
- Sponsor(s)
- Contact
- TARA WELLS at 720-848-0755
or TARA.WELLS@UCDENVER.EDU
- Eligibility and Other Participant Information
- What To Expect : Not available at this time // Not available at this time